Literature DB >> 10950117

Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression.

M H Vaarala1, K Porvari, A Kyllönen, P Vihko.   

Abstract

Prostate cancer tends to become transformed to androgen-independent disease over time when treated by androgen-deprivation therapy. We used two variants of the human prostate cancer cell line LNCaP to study gene expression differences during prostate cancer progression to androgen-independent disease. Production of prostate-specific antigen was regarded as a marker of androgen-dependence and loss of prostate-specific antigen was regarded as a marker of androgen-independence. mRNA from both cell lines was used for cDNA microarray screening. Differential expression of several genes was confirmed by Northern blotting. Monoamine oxidase A, an Expressed Sequence Tag (EST) similar to rat P044, and EST AA412049 were highly overexpressed in androgen-dependent LNCaP cells. Tissue-type plasminogen activator, interferon-inducible protein p78 (MxB), an EST similar to galectin-1, follistatin, fatty acid-binding protein 5, EST AA609749, annexin I, the interferon-inducible gene 1-8U, and phospholipase D1 were highly overexpressed in androgen-independent LNCaP cells. All studied genes had low or no expression in PC-3 cells. The EST similar to rat P044, the EST similar to galectin-1, follistatin, annexin I, and the interferon-inducible gene 1-8U were also expressed in benign prostatic hyperplasia tissue. The Y-linked ribosomal protein S4, Mat-8, and EST AA307912 were highly expressed in benign prostatic hyperplasia tissue. Additionally, both confirmation of differential expression in Northern blots and in situ hybridization were carried out for monoamine oxidase A, the EST similar to rat P044, the EST similar to galectin-1, fatty acid-binding protein 5, and the interferon-inducible gene 1-8U. We identified several potential prostate cancer markers, indicating that the method used is a useful tool for the screening of cancer markers, but other methods, such as in situ hybridization, are needed to further investigate the observations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10950117     DOI: 10.1038/labinvest.3780134

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  29 in total

1.  Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis.

Authors:  H Chaib; E K Cockrell; M A Rubin; J A Macoska
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

2.  Identification of disease-specific genes in chronic pancreatitis using DNA array technology.

Authors:  H Friess; J Ding; J Kleeff; Q Liao; P O Berberat; J Hammer; M W Büchler
Journal:  Ann Surg       Date:  2001-12       Impact factor: 12.969

3.  Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections.

Authors:  Dong Jiang; Jessica M Weidner; Min Qing; Xiao-Ben Pan; Haitao Guo; Chunxiao Xu; Xianchao Zhang; Alex Birk; Jinhong Chang; Pei-Yong Shi; Timothy M Block; Ju-Tao Guo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

4.  Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.

Authors:  Jeff Holzbeierlein; Priti Lal; Eva LaTulippe; Alex Smith; Jaya Satagopan; Liying Zhang; Charles Ryan; Steve Smith; Howard Scher; Peter Scardino; Victor Reuter; William L Gerald
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

5.  Expression and characterization of the FXYD ion transport regulators for NMR structural studies in lipid micelles and lipid bilayers.

Authors:  Kevin J Crowell; Carla M Franzin; Anita Koltay; Sangmin Lee; Anna Maria Lucchese; Bradley C Snyder; Francesca M Marassi
Journal:  Biochim Biophys Acta       Date:  2003-01-31

6.  Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer.

Authors:  Barbara Domazet; Gregory T Maclennan; Antonio Lopez-Beltran; Rodolfo Montironi; Liang Cheng
Journal:  Int J Clin Exp Pathol       Date:  2008-03-15

7.  Androgen regulated genes in human prostate xenografts in mice: relation to BPH and prostate cancer.

Authors:  Harold D Love; S Erin Booton; Braden E Boone; Joan P Breyer; Tatsuki Koyama; Monica P Revelo; Scott B Shappell; Jeffrey R Smith; Simon W Hayward
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

8.  Serum follistatin in patients with prostate cancer metastatic to the bone.

Authors:  Francesca Maria Tumminello; Giuseppe Badalamenti; Fabio Fulfaro; Lorena Incorvaia; Marilena Crescimanno; Carla Flandina; Maria Vittoria Sepporta; Gaetano Leto
Journal:  Clin Exp Metastasis       Date:  2010-07-11       Impact factor: 5.150

Review 9.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

Review 10.  Cellular and physiological roles for phospholipase D1 in cancer.

Authors:  Yi Zhang; Michael A Frohman
Journal:  J Biol Chem       Date:  2014-07-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.